| Polarean's Xenon MRI technology to feature in over 30 studies at American Thoracic Society events |
Polarean Imaging PLC (AIM:POLX, OTC:PLLWF), the AIM-listed medical imaging company, will have its Xenon-based magnetic resonance imaging (MRI) technology showcased in more than 30 clinical studies at the American Thoracic Society's annual meetings in San Francisco this month. The company, which develops imaging platforms designed to assess lung function, has been selected as a featured participant at the ATS Respiratory Innovation Summit, taking place on 16–17 May. |
proactiveinvestors.co.uk |
2025-05-15 15:36:51 |
Czytaj oryginał (ang.) |
| Xenon MRI Featured Prominently at ATS 2025 Across Broad Clinical Spectrum |
30+ studies across diverse conditions illuminate the unique value of functional lung imaging with Xenon MRI 30+ studies across diverse conditions illuminate the unique value of functional lung imaging with Xenon MRI |
globenewswire.com |
2025-05-15 12:49:00 |
Czytaj oryginał (ang.) |
| Xenon to Present at the 2025 RBC Capital Markets Global Healthcare Conference |
VANCOUVER, British Columbia and BOSTON, May 14, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced that the company will present at the 2025 RBC Capital Markets Global Healthcare Conference taking place in New York, NY from May 20-21, 2025. |
globenewswire.com |
2025-05-14 20:01:00 |
Czytaj oryginał (ang.) |
| Xenon Q1 Loss Narrower Than Expected, Pipeline Development in Focus |
XENE incurs narrower-than-estimated first-quarter 2025 loss. Studies on lead candidate, azetukalner, in epilepsy and MDD are progressing well. |
zacks.com |
2025-05-13 17:10:46 |
Czytaj oryginał (ang.) |
| Xenon Pharmaceuticals Inc. (XENE) Q1 2025 Earnings Call Transcript |
Xenon Pharmaceuticals Inc. (NASDAQ:XENE ) Q1 2025 Earnings Conference Call May 12, 2025 4:30 AM ET Corporate Participants Chad Fugere - Vice President, Investor Relations Ian Mortimer - President and Chief Executive Officer Chris Kenney - Chief Medical Officer Sherry Aulin - Chief Financial Officer Conference Call Participants Paul Matteis - Stifel Tessa Romero - JPMorgan Brian Abrahams - RBC Capital Markets Brian Skorney - Baird Myles Minter - William Blair Dylan Shindler - Wedbush Daniel Ni - Goldman Sachs Andrew Tsai - Jefferies Joseph Thome - TD Cowen Operator Thank you for standing by. My name is Carly, and I will be your conference operator today. |
seekingalpha.com |
2025-05-13 02:06:49 |
Czytaj oryginał (ang.) |
| Xenon Reports First Quarter 2025 Financial Results and Provides Business Update |
– Phase 3 azetukalner X-TOLE2 FOS study patient recruitment expected to complete in the next few months with topline data anticipated in early 2026 |
globenewswire.com |
2025-05-12 20:01:00 |
Czytaj oryginał (ang.) |
| Xenon to Report Q1 2025 Financial Results on May 12, 2025 |
VANCOUVER, British Columbia and BOSTON, May 05, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced it will report its first quarter 2025 financial results and provide a business update after the close of U.S. financial markets on Monday, May 12, 2025. |
globenewswire.com |
2025-05-05 20:01:00 |
Czytaj oryginał (ang.) |
| Wall Street Analysts See a 48.15% Upside in Xenon Pharmaceuticals (XENE): Can the Stock Really Move This High? |
The average of price targets set by Wall Street analysts indicates a potential upside of 48.2% in Xenon Pharmaceuticals (XENE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
zacks.com |
2025-05-05 15:01:16 |
Czytaj oryginał (ang.) |
| Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
VANCOUVER, British Columbia and BOSTON, May 02, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced equity inducement grants to four new non-officer employees consisting of an aggregate of 78,600 share options and 1,800 performance share units (“PSUs”). All of the foregoing share options and PSUs were approved by the Compensation Committee of the Company's Board of Directors with an effective date of May 2, 2025 and were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). |
globenewswire.com |
2025-05-02 20:42:00 |
Czytaj oryginał (ang.) |
| Xenon- A Later Stage Story |
Xenon's lead asset, azetukalner, shows promise in treating focal onset seizures with positive phase IIb results and upcoming phase III data expected by end of 2025. Azetukalner's unique Kv7 potassium channel mechanism and rapid onset of action could address unmet needs in treatment-resistant epilepsy and potentially depression. Financially stable, Xenon is well-funded into 2027, with potential $1Bn market opportunity if azetukalner succeeds in focal onset seizures and expands into other indications. |
seekingalpha.com |
2025-04-18 07:36:04 |
Czytaj oryginał (ang.) |
| Xenon Pharmaceuticals Looks Attractive Before Epilepsy Data |
Xenon Pharmaceuticals Inc.'s lead asset, azetukalner (XEN1101), shows promising phase 2b results for focal onset seizures (FOS) and is in phase 3 trials for FOS and PGTCS. Despite failing to meet the primary endpoint in an MDD trial, azetukalner's potential in epilepsy remains strong, with long-term data showing sustained seizure reduction. Financially, Xenon Pharma has a solid cash position, providing a runway of 11–13 quarters, making it an attractive investment at current low prices. |
seekingalpha.com |
2025-04-04 20:23:22 |
Czytaj oryginał (ang.) |
| Xenon to Showcase Long-Term 36-Month Azetukalner Data at AAN 2025 |
VANCOUVER, British Columbia and BOSTON, April 04, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced multiple presentations at the upcoming American Academy of Neurology Annual Meeting (AAN 2025), taking place April 5-9, 2025 in San Diego, CA. Three posters will be presented, including long-term data from the ongoing X-TOLE open-label extension (OLE) study of azetukalner in patients with focal onset seizures (FOS). The Company will also present an exploratory efficacy analysis of FOS seizure subtypes from the X-TOLE study, as well as patient survey findings about the mental health and comorbidity burdens of FOS. |
globenewswire.com |
2025-04-04 12:30:00 |
Czytaj oryginał (ang.) |
| Xenon to Present at Stifel 2025 Virtual CNS Forum |
VANCOUVER, British Columbia and BOSTON, March 12, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced that the company will present at the Stifel 2025 Virtual CNS Forum taking place from March 18-19, 2025. |
globenewswire.com |
2025-03-12 18:01:00 |
Czytaj oryginał (ang.) |
| Xenon Q4 Loss Narrower Than Expected, Pipeline Development in Focus |
XENE reports a narrower-than-expected fourth-quarter 2024 loss. Its development programs for azetukalner in epilepsy and MDD are progressing well. |
zacks.com |
2025-02-28 12:40:45 |
Czytaj oryginał (ang.) |
| Xenon Pharmaceuticals Inc. (XENE) Q4 2024 Earnings Call Transcript |
Xenon Pharmaceuticals Inc. (NASDAQ:XENE ) Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ET Company Participants Chad Fugere - Vice President, Investor Relations Ian Mortimer - President and Chief Executive Officer Chris Kenney - Chief Medical Officer Sherry Aulin - Chief Financial Officer Conference Call Participants Paul Matteis - Stifel Caroline Poacher - JPMorgan Brian Skorney - Baird Jason Gerberry - Bank of America Sarah Schram - William Blair Laura Chico - Wedbush Securities Joseph Thome - TD Cowen Douglas Tsao - H.C. Wainwright Operator Hello and thank you for standing by. |
seekingalpha.com |
2025-02-28 01:53:54 |
Czytaj oryginał (ang.) |
| Xenon Reports Fourth Quarter & Full Year 2024 Financial Results and Business Update |
– Phase 3 topline data from azetukalner FOS epilepsy program planned for H2 2025 in support of NDA filing and potential commercial launch |
globenewswire.com |
2025-02-27 18:01:00 |
Czytaj oryginał (ang.) |
| Xenon to Present at the 45th Annual TD Cowen Healthcare Conference |
VANCOUVER, British Columbia and BOSTON, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced that the company will present at the 45th Annual TD Cowen Healthcare Conference taking place in Boston, MA from March 3-5, 2025. |
globenewswire.com |
2025-02-25 18:01:00 |
Czytaj oryginał (ang.) |
| Xenon to Report Q4 and Full Year 2024 Financial Results on February 27, 2025 |
VANCOUVER, British Columbia and BOSTON, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced it will report its fourth quarter 2024 financial results after the close of U.S. financial markets on Thursday, February 27, 2025. |
globenewswire.com |
2025-02-20 18:01:00 |
Czytaj oryginał (ang.) |
| XENON Systems Partners with Netris to Deliver Multi-tenant GPU Cloud Networking Solutions for AI/ML Cloud Providers in the Region |
SANTA CLARA, Calif.--(BUSINESS WIRE)-- #GPU--Netris, an innovative software company specializing in cloud-like network automation and abstraction, is excited to announce a partnership with XENON Systems, a premier high-performance computing and AI infrastructure specialist based in Australia. This collaboration aims to expand offering and integration of Netris multi-tenant GPU Cloud networking technologies within XENON Systems' customer base. Addressing the Demands of AI and Data-Intensive Workloads T. |
businesswire.com |
2025-02-12 14:00:00 |
Czytaj oryginał (ang.) |
| Xenon Pharmaceuticals: 2025 Could Be Pivotal For Azetukalner's Epilepsy Potential |
Xenon Pharmaceuticals' Azetukalner has good Phase 2 data for MDD using Kv7 potassium channels. This also gives it a good safety profile. The company has robust financials with a runway that should last into 2027 or more. So, I think it should have enough resources to take its late-stage pipeline to approval. Epilepsy and MDD have an attractive TAM of several billions of dollars in the US and abroad. XENE could tap into these niche markets over time. |
seekingalpha.com |
2025-01-16 03:41:01 |
Czytaj oryginał (ang.) |
| Xenon Outlines Key Corporate Milestone Opportunities for 2025 |
– Topline data from the first Phase 3 FOS study anticipated in H2 2025 representing major milestone in support of NDA filing and potential launch of azetukalner |
globenewswire.com |
2025-01-13 10:30:00 |
Czytaj oryginał (ang.) |
| Xenon to Present at the 43rd Annual J.P. Morgan Healthcare Conference |
VANCOUVER, British Columbia and BOSTON, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced that the company will present at the 43rd Annual J.P. Morgan Healthcare Conference taking place in San Francisco, CA from January 13-16, 2025. |
globenewswire.com |
2025-01-07 10:30:00 |
Czytaj oryginał (ang.) |
| Xenon Pharmaceuticals (XENE) Up 2.4% Since Last Earnings Report: Can It Continue? |
Xenon Pharmaceuticals (XENE) reported earnings 30 days ago. What's next for the stock? |
zacks.com |
2024-12-12 14:36:07 |
Czytaj oryginał (ang.) |
| Xenon Showcases New Long-Term Azetukalner Data from X-TOLE OLE Study in FOS at AES 2024 |
– OLE data shows sustained monthly reduction in seizure frequency, impressive seizure freedom rates, and consistent AE safety profile suggesting long-term efficacy and tolerability of azetukalner |
globenewswire.com |
2024-12-06 18:01:00 |
Czytaj oryginał (ang.) |
| Xenon to Showcase New Long-Term Azetukalner Data at AES 2024 |
VANCOUVER, British Columbia and BOSTON, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced multiple presentations at the upcoming American Epilepsy Society Annual Meeting (AES 2024), taking place December 6-10, 2024 at the Los Angeles Convention Center in Los Angeles, CA. Five posters will be presented, featuring new long-term data from the ongoing X-TOLE open-label extension study of azetukalner in patients with focal onset seizures (FOS), the mental health burden and comorbidity burdens of focal onset seizures, as well as new pre-clinical data from the Company's early-stage Nav1.1 program. |
globenewswire.com |
2024-11-25 10:30:00 |
Czytaj oryginał (ang.) |
| Xenon to Present at Upcoming Investor Conferences |
VANCOUVER, British Columbia and BOSTON, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced that the Company will present at two upcoming investor conferences. |
globenewswire.com |
2024-11-13 18:01:00 |
Czytaj oryginał (ang.) |
| Xenon Q3 Loss Narrower Than Expected, Pipeline Development in Focus |
XENE reports a narrower-than-expected third-quarter 2024 loss. Its development programs for azetukalner in epilepsy and MDD are progressing well. |
zacks.com |
2024-11-13 13:51:07 |
Czytaj oryginał (ang.) |
| Xenon Pharmaceuticals Inc. (XENE) Q3 2024 Earnings Call Transcript |
Xenon Pharmaceuticals Inc. (NASDAQ:XENE ) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Chad Fugere - Vice President, Investor Relations Ian Mortimer - President and Chief Executive Officer Chris Kenney - Chief Medical Officer Sherry Aulin - Chief Financial Officer Chris Von Seggern - Chief Commercial Officer Conference Call Participants Caroline Pocher - JPMorgan Andrew Tsai - Jefferies Brian Abrahams - RBC Capital Markets Luke Herrmann - Baird Jason Gerberry - Bank of America Sarah Schram - William Blair Paul Choi - Goldman Sachs Danielle Brill - Raymond James Marc Goodman - Leerink Partners Joseph Thome - TD Cowen Dylan Shindler - Wedbush Securities Operator Good afternoon, and thank you for standing by. At this time, I'd like to welcome everyone to Xenon Pharmaceuticals, Inc. Third Quarter 2024 Earnings Conference Call. |
seekingalpha.com |
2024-11-13 00:49:58 |
Czytaj oryginał (ang.) |
| Xenon Reports Q3 2024 Financial Results and Business Update |
– Phase 3 epilepsy program advancing with X-TOLE2 topline FOS data anticipated in H2 2025 – Long-term azetukalner results from X-TOLE open-label extension study in FOS to be presented at AES – Phase 3 MDD program on track with X-NOVA2 study expected to initiate by year-end – Expanding ion channel portfolio includes multiple candidates advancing towards IND filings in 2025 – Recent appointment of Matt Ronsheim, experienced pharmaceutical executive joining Xenon's senior executive team as Chief Operating Officer – Conference call at 4:30 pm ET today VANCOUVER, British Columbia and BOSTON, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today provided a business update and reported financial results for the third quarter ended September 30, 2024. “Xenon's leadership in the Kv7 landscape is unmatched as our lead molecule, azetukalner, represents the only highly potent, selective Kv7 potassium channel opener in development for multiple indications that is backed by long-term efficacy and safety data with over 600-patient years of exposure in patients living with epilepsy. |
globenewswire.com |
2024-11-12 18:01:00 |
Czytaj oryginał (ang.) |
| Xenon to Report Q3 2024 Financial Results on November 12, 2024 |
VANCOUVER, British Columbia and BOSTON, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced it will report its third quarter 2024 financial results after the close of U.S. financial markets on Tuesday, November 12, 2024. |
globenewswire.com |
2024-11-05 18:01:00 |
Czytaj oryginał (ang.) |
| Xenon to Present at BofA Securities 2024 CNS Therapeutics Virtual Conference |
VANCOUVER, British Columbia and BOSTON, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced its participation in the upcoming BofA Securities 2024 CNS Therapeutics Virtual Conference taking place October 7, 2024. |
globenewswire.com |
2024-10-02 20:28:00 |
Czytaj oryginał (ang.) |
| Xenon Showcases Azetukalner Data at 15th European Epilepsy Congress |
VANCOUVER, British Columbia and BOSTON, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced three poster presentations at the 15th European Epilepsy Congress (EEC) taking place in Rome, Italy. Azetukalner, a novel, potent Kv7 channel opener, is the most advanced, clinically validated potassium channel modulator in late-stage development for multiple indications, including focal onset seizures (FOS), primary generalized tonic-clonic seizures (PGTCS) and major depressive disorder (MDD). |
globenewswire.com |
2024-09-09 12:30:00 |
Czytaj oryginał (ang.) |
| Polarean Imaging appoints Xenon MRI specialist as its chief medical advisor |
Polarean Imaging PLC (AIM:POLX, OTC:PLLWF) has appointed Dr Chase Hall as chief medical advisor. An associate professor at the University of Kansas Medical Center, Hall specialises in pulmonary care and imaging biomarkers using Xenon MRI. |
proactiveinvestors.co.uk |
2024-08-28 07:08:38 |
Czytaj oryginał (ang.) |
| Xenon (XENE) Focuses on Neuro Candidate Amid Pipeline Woe |
Xenon's (XENE) clinical studies of azetukalner in epilepsy and other neurological disorders are progressing well. However, any setback is set to hurt the stock in the absence of a deep pipeline. |
zacks.com |
2024-08-21 15:50:31 |
Czytaj oryginał (ang.) |
| Xenon Pharmaceuticals, Inc. (XENE) Q2 2024 Earnings Call Transcript |
Xenon Pharmaceuticals, Inc. (NASDAQ:XENE ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Chad Fugere - VP, IR Ian Mortimer - President & CEO Chris Kenney - CMO Sherry Aulin - CFO Chris Von Seggern - CCO Conference Call Participants Paul Matteis - Stifel Leo Leung - RBC Capital Markets Tessa Romero - J.P. Morgan Dina Ramadane - Bank of America Luke Herrmann - Baird Andrew Tsai - Jefferies Paul Choi - Goldman Sachs Peyton Bohnsack - TD Cowen Dylan Shindler - Wedbush Securities Basma Radwan - Leerink Partners Operator Thank you for standing by. |
seekingalpha.com |
2024-08-09 16:10:30 |
Czytaj oryginał (ang.) |
| Xenon (XENE) Q2 Earnings Miss, Pipeline in Focus, Stock Down |
Xenon (XENE) is down as it reports a wider-than-expected second-quarter 2024 loss. Its development programs for azetukalner in epilepsy and MDD are progressing well. |
zacks.com |
2024-08-09 15:21:13 |
Czytaj oryginał (ang.) |
| Xenon Reports Q2 2024 Financial Results and Business Update |
— Phase 3 epilepsy program progressing with X-TOLE2 topline FOS data anticipated in H2 2025 — MDD program on track with Phase 3 study expected to initiate in H2 2024— Multiple Kv7 and Nav1.7 candidates progressing towards development with INDs expected in 2025— Conference call at 4:30 pm ET today |
globenewswire.com |
2024-08-08 20:01:00 |
Czytaj oryginał (ang.) |
| Xenon to Report Q2 2024 Financial Results on August 8, 2024 |
VANCOUVER, British Columbia, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced it will report its second quarter 2024 financial and operating results after the close of U.S. financial markets on Thursday, August 8, 2024. Conference Call/Webcast Information: Date: Thursday, August 8, 2024 Time: 4:30 pm Eastern Time (1:30 pm Pacific Time) Webcast: Pre-register here Dial-In: (800) 715-9871 toll-free, or (646) 307-1963 for international callers Conference ID: 1631616 The live audio webcast can be accessed on the Investors section of the Xenon website. |
globenewswire.com |
2024-08-01 20:01:00 |
Czytaj oryginał (ang.) |
| Xenon Gas Market to Reach USD 270.5 Million at a CAGR of 5.2% through 2034 Amid Bolstering Usage in MRI Scanning Machines and High-power Lamps | Future Market Insights, Inc. |
Global Xenon Gas Market Report 2024-2034: Aerospace & Aircraft Industry Emerges as the Leading Consumer, with Significant Usage in Satellite Propulsion. The healthcare industry, a sector witnessing exponential global investment, presents substantial market opportunities for xenon gas manufacturers. Global Xenon Gas Market Report 2024-2034: Aerospace & Aircraft Industry Emerges as the Leading Consumer, with Significant Usage in Satellite Propulsion. The healthcare industry, a sector witnessing exponential global investment, presents substantial market opportunities for xenon gas manufacturers. |
globenewswire.com |
2024-07-30 11:30:00 |
Czytaj oryginał (ang.) |
| Xenon Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference |
VANCOUVER, British Columbia, June 05, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company, today announced that the company will present at the Goldman Sachs 45th Annual Global Healthcare Conference taking place June 10-13, 2024 in Miami, FL. |
globenewswire.com |
2024-06-05 20:01:00 |
Czytaj oryginał (ang.) |
| Xenon Pharmaceuticals Presents Data from Phase 2 X-NOVA Clinical Trial of Azetukalner in Major Depressive Disorder at the American Society of Clinical Psychopharmacology 2024 Annual Meeting |
VANCOUVER, British Columbia, May 28, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company, announced data presentations highlighting azetukalner (XEN1101) clinical data in major depressive disorder (MDD) at the American Society of Clinical Psychopharmacology (ASCP) 2024 Annual Meeting in Miami, FL. |
globenewswire.com |
2024-05-28 12:30:00 |
Czytaj oryginał (ang.) |
| Xenon (XENE) Q1 Earnings Beat Estimates, Pipeline in Focus |
Xenon (XENE) reports better-than-expected first-quarter 2024 earnings. Its development programs for azetukalner in epilepsy and MDD are progressing well. |
zacks.com |
2024-05-10 13:21:06 |
Czytaj oryginał (ang.) |